| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urinary Bladder, Overactive | 39 | 2021 | 90 | 8.790 |
Why?
|
| Urinary Incontinence, Stress | 53 | 2023 | 196 | 7.680 |
Why?
|
| Urinary Incontinence | 53 | 2020 | 213 | 6.480 |
Why?
|
| Muscarinic Antagonists | 25 | 2012 | 58 | 5.230 |
Why?
|
| Mandelic Acids | 20 | 2013 | 20 | 3.740 |
Why?
|
| Vagina | 18 | 2022 | 173 | 3.520 |
Why?
|
| Uterine Prolapse | 15 | 2022 | 80 | 3.120 |
Why?
|
| Cystitis, Interstitial | 12 | 2023 | 53 | 2.740 |
Why?
|
| Pelvic Floor | 19 | 2022 | 85 | 2.640 |
Why?
|
| Urethra | 21 | 2023 | 115 | 2.500 |
Why?
|
| Urinary Incontinence, Urge | 11 | 2021 | 45 | 2.430 |
Why?
|
| Urinary Bladder Diseases | 13 | 2012 | 41 | 2.350 |
Why?
|
| Pelvic Organ Prolapse | 9 | 2022 | 154 | 2.250 |
Why?
|
| Surgical Mesh | 10 | 2022 | 122 | 2.230 |
Why?
|
| Urodynamics | 36 | 2023 | 122 | 2.180 |
Why?
|
| Quality of Life | 29 | 2021 | 1662 | 2.180 |
Why?
|
| Wound Healing | 7 | 2012 | 359 | 1.980 |
Why?
|
| Electric Stimulation Therapy | 13 | 2021 | 46 | 1.940 |
Why?
|
| Benzhydryl Compounds | 11 | 2012 | 44 | 1.940 |
Why?
|
| Female | 192 | 2023 | 46011 | 1.840 |
Why?
|
| Nortropanes | 9 | 2011 | 10 | 1.830 |
Why?
|
| Surveys and Questionnaires | 25 | 2020 | 2612 | 1.780 |
Why?
|
| Urologic Surgical Procedures | 11 | 2018 | 147 | 1.730 |
Why?
|
| Gynecologic Surgical Procedures | 9 | 2019 | 148 | 1.640 |
Why?
|
| Treatment Outcome | 64 | 2023 | 8203 | 1.460 |
Why?
|
| Urinary Bladder | 22 | 2023 | 246 | 1.450 |
Why?
|
| Middle Aged | 118 | 2021 | 25863 | 1.420 |
Why?
|
| Aged | 99 | 2020 | 19077 | 1.390 |
Why?
|
| Humans | 203 | 2023 | 89063 | 1.310 |
Why?
|
| Delivery, Obstetric | 10 | 2018 | 118 | 1.290 |
Why?
|
| Fecal Incontinence | 8 | 2014 | 57 | 1.190 |
Why?
|
| Patient Satisfaction | 8 | 2018 | 461 | 1.170 |
Why?
|
| Urology | 11 | 2016 | 117 | 1.100 |
Why?
|
| Terminology as Topic | 10 | 2011 | 221 | 1.070 |
Why?
|
| Skin | 4 | 2012 | 581 | 1.070 |
Why?
|
| Nocturia | 4 | 2023 | 19 | 0.990 |
Why?
|
| Prostheses and Implants | 8 | 2011 | 124 | 0.990 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 3 | 2019 | 15 | 0.980 |
Why?
|
| Suburethral Slings | 6 | 2018 | 75 | 0.960 |
Why?
|
| Pentosan Sulfuric Polyester | 5 | 2008 | 7 | 0.940 |
Why?
|
| Dimethyl Sulfoxide | 5 | 2023 | 38 | 0.930 |
Why?
|
| Cresols | 9 | 2009 | 17 | 0.910 |
Why?
|
| Ligaments | 4 | 2017 | 33 | 0.890 |
Why?
|
| Phenylpropanolamine | 8 | 2009 | 15 | 0.870 |
Why?
|
| Botulinum Toxins, Type A | 7 | 2018 | 50 | 0.850 |
Why?
|
| Menopause | 3 | 2012 | 76 | 0.830 |
Why?
|
| Skin Transplantation | 2 | 2020 | 183 | 0.820 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2012 | 89 | 0.810 |
Why?
|
| Double-Blind Method | 24 | 2013 | 1714 | 0.780 |
Why?
|
| Implantable Neurostimulators | 1 | 2021 | 12 | 0.770 |
Why?
|
| Pelvic Floor Disorders | 4 | 2014 | 55 | 0.770 |
Why?
|
| Parasympatholytics | 3 | 2009 | 19 | 0.770 |
Why?
|
| Sexuality | 2 | 2014 | 41 | 0.750 |
Why?
|
| Adult | 76 | 2019 | 26507 | 0.750 |
Why?
|
| Urologic Diseases | 5 | 2013 | 44 | 0.740 |
Why?
|
| Aged, 80 and over | 36 | 2018 | 6777 | 0.740 |
Why?
|
| Cystoscopy | 7 | 2008 | 39 | 0.710 |
Why?
|
| Pregnancy, Multiple | 3 | 2005 | 37 | 0.700 |
Why?
|
| Collagen | 5 | 2007 | 293 | 0.690 |
Why?
|
| Urination Disorders | 7 | 2004 | 50 | 0.680 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2014 | 559 | 0.660 |
Why?
|
| Suture Techniques | 4 | 2017 | 140 | 0.660 |
Why?
|
| Prospective Studies | 28 | 2023 | 4273 | 0.660 |
Why?
|
| Postoperative Complications | 14 | 2011 | 2275 | 0.650 |
Why?
|
| Urinary Catheterization | 4 | 2004 | 36 | 0.620 |
Why?
|
| Follow-Up Studies | 22 | 2019 | 3657 | 0.620 |
Why?
|
| Pregnancy Complications | 3 | 2018 | 345 | 0.620 |
Why?
|
| Triamcinolone | 3 | 2023 | 18 | 0.610 |
Why?
|
| Counseling | 2 | 2018 | 163 | 0.610 |
Why?
|
| Tibial Nerve | 5 | 2021 | 14 | 0.610 |
Why?
|
| Pelvic Pain | 4 | 2008 | 84 | 0.600 |
Why?
|
| Rabbits | 7 | 2012 | 638 | 0.590 |
Why?
|
| Retrospective Studies | 26 | 2018 | 9003 | 0.580 |
Why?
|
| Ovariectomy | 3 | 2012 | 81 | 0.570 |
Why?
|
| Cholinergic Antagonists | 6 | 2019 | 27 | 0.550 |
Why?
|
| Pain, Postoperative | 2 | 2017 | 251 | 0.540 |
Why?
|
| Cesarean Section | 5 | 2018 | 140 | 0.540 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2017 | 345 | 0.540 |
Why?
|
| Women's Health | 4 | 2010 | 102 | 0.530 |
Why?
|
| Colpotomy | 2 | 2012 | 4 | 0.510 |
Why?
|
| Benzilates | 9 | 2011 | 9 | 0.510 |
Why?
|
| International Cooperation | 6 | 2010 | 125 | 0.500 |
Why?
|
| Urethral Diseases | 3 | 2006 | 15 | 0.500 |
Why?
|
| Neuromuscular Agents | 4 | 2016 | 26 | 0.500 |
Why?
|
| Recurrence | 12 | 2020 | 1140 | 0.500 |
Why?
|
| Magnetics | 4 | 2003 | 41 | 0.490 |
Why?
|
| Administration, Cutaneous | 9 | 2013 | 60 | 0.490 |
Why?
|
| Communication | 1 | 2018 | 457 | 0.480 |
Why?
|
| Tetrahydroisoquinolines | 3 | 2009 | 4 | 0.470 |
Why?
|
| Pain | 4 | 2023 | 400 | 0.470 |
Why?
|
| Pregnancy | 17 | 2023 | 3009 | 0.470 |
Why?
|
| Durapatite | 2 | 2011 | 28 | 0.460 |
Why?
|
| Vesico-Ureteral Reflux | 1 | 2014 | 28 | 0.460 |
Why?
|
| Male | 49 | 2021 | 42251 | 0.460 |
Why?
|
| Quinuclidines | 3 | 2009 | 26 | 0.460 |
Why?
|
| Delayed-Action Preparations | 11 | 2011 | 110 | 0.450 |
Why?
|
| Rectocele | 2 | 2005 | 7 | 0.450 |
Why?
|
| Models, Economic | 1 | 2013 | 62 | 0.440 |
Why?
|
| Antidiuretic Agents | 1 | 2013 | 3 | 0.440 |
Why?
|
| Female Urogenital Diseases | 2 | 2010 | 10 | 0.440 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2013 | 12 | 0.430 |
Why?
|
| Time Factors | 15 | 2021 | 5320 | 0.430 |
Why?
|
| Symptom Assessment | 1 | 2013 | 66 | 0.430 |
Why?
|
| Uterus | 1 | 2014 | 222 | 0.430 |
Why?
|
| Safety | 2 | 2012 | 149 | 0.430 |
Why?
|
| Family Health | 1 | 2013 | 162 | 0.420 |
Why?
|
| Severity of Illness Index | 11 | 2013 | 1837 | 0.420 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2013 | 67 | 0.420 |
Why?
|
| Cohort Studies | 12 | 2018 | 2863 | 0.420 |
Why?
|
| Sutures | 2 | 2011 | 53 | 0.410 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2012 | 29 | 0.410 |
Why?
|
| Societies, Medical | 4 | 2010 | 570 | 0.410 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 1706 | 0.400 |
Why?
|
| Drug Administration Schedule | 12 | 2013 | 894 | 0.400 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2011 | 6 | 0.390 |
Why?
|
| Syringes | 2 | 2002 | 13 | 0.390 |
Why?
|
| Rectal Fistula | 1 | 2011 | 18 | 0.380 |
Why?
|
| Gynecology | 4 | 2016 | 129 | 0.380 |
Why?
|
| Multivariate Analysis | 8 | 2013 | 988 | 0.370 |
Why?
|
| Disease Management | 1 | 2013 | 329 | 0.370 |
Why?
|
| Pressure | 8 | 2006 | 165 | 0.370 |
Why?
|
| Multiple Sclerosis | 1 | 2013 | 272 | 0.370 |
Why?
|
| Pelvis | 3 | 2005 | 96 | 0.360 |
Why?
|
| Reoperation | 6 | 2020 | 598 | 0.360 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2013 | 1940 | 0.350 |
Why?
|
| Biocompatible Materials | 1 | 2011 | 198 | 0.350 |
Why?
|
| Tartrates | 3 | 2004 | 6 | 0.350 |
Why?
|
| Abdomen | 4 | 2007 | 122 | 0.340 |
Why?
|
| Adolescent | 22 | 2021 | 9237 | 0.340 |
Why?
|
| Dermis | 2 | 2009 | 28 | 0.340 |
Why?
|
| Administration, Intravesical | 5 | 2023 | 32 | 0.340 |
Why?
|
| Craniosynostoses | 2 | 2021 | 77 | 0.330 |
Why?
|
| Urinary Retention | 3 | 2016 | 42 | 0.330 |
Why?
|
| Self Report | 2 | 2021 | 295 | 0.330 |
Why?
|
| Tolterodine Tartrate | 8 | 2009 | 15 | 0.330 |
Why?
|
| Work | 1 | 2009 | 15 | 0.330 |
Why?
|
| Recovery of Function | 1 | 2010 | 292 | 0.320 |
Why?
|
| Efficiency | 1 | 2009 | 40 | 0.320 |
Why?
|
| Estrogens | 3 | 2023 | 201 | 0.320 |
Why?
|
| Developmental Disabilities | 2 | 2021 | 202 | 0.310 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2008 | 48 | 0.310 |
Why?
|
| Narcotics | 1 | 2008 | 70 | 0.300 |
Why?
|
| Probability | 8 | 2008 | 353 | 0.300 |
Why?
|
| Twins, Monozygotic | 4 | 2010 | 57 | 0.300 |
Why?
|
| Granulation Tissue | 1 | 2007 | 15 | 0.290 |
Why?
|
| Risk Assessment | 10 | 2019 | 2290 | 0.280 |
Why?
|
| Surgical Tape | 1 | 2006 | 4 | 0.280 |
Why?
|
| Injections | 2 | 2005 | 116 | 0.280 |
Why?
|
| Urological Agents | 2 | 2018 | 5 | 0.280 |
Why?
|
| Wounds, Penetrating | 1 | 2007 | 57 | 0.270 |
Why?
|
| Constipation | 5 | 2010 | 63 | 0.270 |
Why?
|
| Hematuria | 3 | 2008 | 50 | 0.270 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2008 | 170 | 0.270 |
Why?
|
| Risk Factors | 12 | 2013 | 5466 | 0.260 |
Why?
|
| Reproducibility of Results | 7 | 2013 | 2752 | 0.260 |
Why?
|
| Age Factors | 8 | 2012 | 1867 | 0.260 |
Why?
|
| Medication Adherence | 2 | 2018 | 138 | 0.260 |
Why?
|
| Postoperative Care | 2 | 2004 | 229 | 0.260 |
Why?
|
| Intrauterine Devices | 1 | 2005 | 28 | 0.260 |
Why?
|
| Fascia Lata | 1 | 2005 | 7 | 0.260 |
Why?
|
| Gels | 5 | 2013 | 49 | 0.260 |
Why?
|
| Dehydration | 1 | 2005 | 20 | 0.260 |
Why?
|
| Logistic Models | 6 | 2008 | 1212 | 0.250 |
Why?
|
| Colposcopy | 1 | 2005 | 16 | 0.250 |
Why?
|
| Dyspareunia | 1 | 2005 | 19 | 0.250 |
Why?
|
| Solvents | 1 | 2005 | 96 | 0.250 |
Why?
|
| Sweden | 3 | 2014 | 40 | 0.240 |
Why?
|
| Psychometrics | 5 | 2014 | 329 | 0.240 |
Why?
|
| Cystitis | 1 | 2004 | 14 | 0.240 |
Why?
|
| Equipment Design | 2 | 2021 | 415 | 0.240 |
Why?
|
| Surgical Procedures, Operative | 1 | 2007 | 205 | 0.240 |
Why?
|
| Urinary Tract Infections | 3 | 2021 | 76 | 0.230 |
Why?
|
| Anal Canal | 3 | 2011 | 88 | 0.230 |
Why?
|
| Elective Surgical Procedures | 1 | 2005 | 126 | 0.230 |
Why?
|
| Sexual Dysfunction, Physiological | 3 | 2013 | 69 | 0.230 |
Why?
|
| Transplantation, Heterologous | 1 | 2005 | 370 | 0.230 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2008 | 395 | 0.230 |
Why?
|
| Eosinophilia | 1 | 2004 | 84 | 0.230 |
Why?
|
| Exercise Therapy | 2 | 2002 | 81 | 0.230 |
Why?
|
| Delivery of Health Care | 1 | 2008 | 434 | 0.220 |
Why?
|
| Urination | 5 | 2012 | 37 | 0.220 |
Why?
|
| Puerperal Disorders | 1 | 2003 | 32 | 0.220 |
Why?
|
| Prevalence | 4 | 2014 | 1240 | 0.220 |
Why?
|
| Muscle Contraction | 4 | 2014 | 284 | 0.220 |
Why?
|
| Administration, Oral | 6 | 2013 | 682 | 0.220 |
Why?
|
| Parity | 5 | 2011 | 96 | 0.210 |
Why?
|
| Bupivacaine | 3 | 2023 | 45 | 0.210 |
Why?
|
| Allografts | 2 | 2020 | 181 | 0.210 |
Why?
|
| Random Allocation | 3 | 2012 | 328 | 0.210 |
Why?
|
| Reference Values | 7 | 2013 | 661 | 0.210 |
Why?
|
| Feasibility Studies | 3 | 2021 | 779 | 0.210 |
Why?
|
| Mothers | 1 | 2003 | 142 | 0.200 |
Why?
|
| Predictive Value of Tests | 10 | 2012 | 1715 | 0.200 |
Why?
|
| Prosthesis Implantation | 2 | 2021 | 126 | 0.200 |
Why?
|
| Polyglactin 910 | 1 | 2001 | 5 | 0.200 |
Why?
|
| Trimethoprim | 1 | 2021 | 15 | 0.190 |
Why?
|
| Drug Therapy, Combination | 4 | 2017 | 783 | 0.190 |
Why?
|
| Adaptation, Psychological | 2 | 2021 | 166 | 0.190 |
Why?
|
| Urogenital Surgical Procedures | 2 | 2011 | 10 | 0.190 |
Why?
|
| Glutaral | 1 | 2000 | 5 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 1096 | 0.180 |
Why?
|
| Heparin | 2 | 2023 | 185 | 0.180 |
Why?
|
| Animals | 9 | 2012 | 27317 | 0.180 |
Why?
|
| Diffusion of Innovation | 1 | 2001 | 71 | 0.180 |
Why?
|
| Transplants | 2 | 2011 | 41 | 0.180 |
Why?
|
| Epidemiologic Methods | 2 | 2010 | 60 | 0.180 |
Why?
|
| Acetylcholine Release Inhibitors | 2 | 2016 | 3 | 0.180 |
Why?
|
| Evidence-Based Medicine | 6 | 2011 | 433 | 0.170 |
Why?
|
| Incidence | 6 | 2019 | 1592 | 0.170 |
Why?
|
| Electric Stimulation | 1 | 2000 | 354 | 0.170 |
Why?
|
| Minimally Invasive Surgical Procedures | 3 | 2014 | 251 | 0.170 |
Why?
|
| Solifenacin Succinate | 3 | 2009 | 6 | 0.160 |
Why?
|
| Urinary Sphincter, Artificial | 1 | 1999 | 14 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2011 | 833 | 0.160 |
Why?
|
| Condylomata Acuminata | 3 | 1987 | 15 | 0.160 |
Why?
|
| Urinary Tract | 2 | 2013 | 35 | 0.160 |
Why?
|
| Syndrome | 3 | 2019 | 449 | 0.160 |
Why?
|
| Electrodes, Implanted | 1 | 2019 | 177 | 0.150 |
Why?
|
| Cryosurgery | 2 | 1989 | 52 | 0.150 |
Why?
|
| Pubic Bone | 3 | 2004 | 9 | 0.150 |
Why?
|
| Parturition | 1 | 2018 | 21 | 0.150 |
Why?
|
| Secondary Prevention | 3 | 2005 | 158 | 0.150 |
Why?
|
| Chronic Disease | 5 | 2010 | 948 | 0.150 |
Why?
|
| Observational Studies as Topic | 1 | 2018 | 49 | 0.150 |
Why?
|
| Sacrococcygeal Region | 1 | 2017 | 9 | 0.150 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 129 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2016 | 531 | 0.150 |
Why?
|
| Pain Measurement | 2 | 2017 | 328 | 0.150 |
Why?
|
| Hernia, Ventral | 1 | 1997 | 24 | 0.150 |
Why?
|
| Cystostomy | 1 | 1997 | 15 | 0.140 |
Why?
|
| Hysterectomy | 2 | 2008 | 151 | 0.140 |
Why?
|
| Vulvar Diseases | 2 | 2008 | 8 | 0.140 |
Why?
|
| Odds Ratio | 5 | 2008 | 684 | 0.140 |
Why?
|
| Case-Control Studies | 3 | 2018 | 1855 | 0.130 |
Why?
|
| Clinical Trials as Topic | 2 | 2013 | 1149 | 0.130 |
Why?
|
| Illinois | 1 | 2017 | 472 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 1998 | 242 | 0.130 |
Why?
|
| Ultrasonography | 3 | 2018 | 711 | 0.130 |
Why?
|
| Lumbosacral Plexus | 2 | 2005 | 9 | 0.130 |
Why?
|
| Combined Modality Therapy | 2 | 2010 | 1710 | 0.130 |
Why?
|
| Postoperative Period | 3 | 2006 | 301 | 0.130 |
Why?
|
| Cystocele | 2 | 2019 | 7 | 0.130 |
Why?
|
| Child | 5 | 2021 | 7149 | 0.130 |
Why?
|
| Xerostomia | 3 | 2004 | 10 | 0.120 |
Why?
|
| Prolapse | 2 | 2005 | 10 | 0.120 |
Why?
|
| Young Adult | 8 | 2018 | 6288 | 0.120 |
Why?
|
| Anatomic Landmarks | 1 | 2014 | 30 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2010 | 1591 | 0.120 |
Why?
|
| Urinary Bladder, Neurogenic | 2 | 2001 | 25 | 0.120 |
Why?
|
| Compliance | 1 | 2014 | 21 | 0.120 |
Why?
|
| Analysis of Variance | 4 | 2004 | 901 | 0.120 |
Why?
|
| Physician-Patient Relations | 2 | 2018 | 625 | 0.120 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1067 | 0.120 |
Why?
|
| Surgeons | 1 | 2018 | 247 | 0.110 |
Why?
|
| Muscles | 2 | 1991 | 193 | 0.110 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2013 | 14 | 0.110 |
Why?
|
| Medication Therapy Management | 1 | 2013 | 16 | 0.110 |
Why?
|
| Diabetes Complications | 1 | 2014 | 170 | 0.110 |
Why?
|
| Patient Safety | 2 | 2013 | 216 | 0.110 |
Why?
|
| Patient Compliance | 2 | 2012 | 230 | 0.110 |
Why?
|
| Drug Administration Routes | 1 | 2012 | 19 | 0.110 |
Why?
|
| Internal Medicine | 1 | 2016 | 355 | 0.100 |
Why?
|
| Evaluation Studies as Topic | 3 | 2007 | 270 | 0.100 |
Why?
|
| Sex Factors | 2 | 2012 | 1063 | 0.100 |
Why?
|
| Confidence Intervals | 3 | 2004 | 225 | 0.100 |
Why?
|
| Osteomyelitis | 2 | 2004 | 55 | 0.100 |
Why?
|
| Biofeedback, Psychology | 2 | 2007 | 13 | 0.100 |
Why?
|
| United States | 9 | 2012 | 6955 | 0.100 |
Why?
|
| Health Status Indicators | 1 | 2012 | 103 | 0.100 |
Why?
|
| Medical History Taking | 2 | 2008 | 81 | 0.100 |
Why?
|
| Age Distribution | 1 | 2012 | 200 | 0.100 |
Why?
|
| Equipment Reuse | 2 | 2002 | 7 | 0.100 |
Why?
|
| Injections, Intramuscular | 3 | 2016 | 64 | 0.100 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 282 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2001 | 1041 | 0.100 |
Why?
|
| Cognition | 3 | 2021 | 580 | 0.090 |
Why?
|
| Prosthesis Failure | 1 | 2011 | 116 | 0.090 |
Why?
|
| Risk | 4 | 2006 | 657 | 0.090 |
Why?
|
| Electromagnetic Phenomena | 2 | 2001 | 18 | 0.090 |
Why?
|
| Diverticulum | 1 | 2011 | 45 | 0.090 |
Why?
|
| Perineum | 1 | 2011 | 36 | 0.090 |
Why?
|
| Cost Savings | 2 | 2002 | 69 | 0.090 |
Why?
|
| Polytetrafluoroethylene | 1 | 2011 | 74 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3443 | 0.090 |
Why?
|
| Placebos | 1 | 2011 | 214 | 0.090 |
Why?
|
| Depression | 1 | 2014 | 503 | 0.090 |
Why?
|
| Abscess | 1 | 2011 | 94 | 0.090 |
Why?
|
| Vancomycin | 1 | 2011 | 73 | 0.090 |
Why?
|
| Drug Interactions | 1 | 2011 | 245 | 0.090 |
Why?
|
| Rectum | 2 | 2010 | 148 | 0.090 |
Why?
|
| Blood Glucose | 1 | 2014 | 836 | 0.090 |
Why?
|
| Physical Examination | 2 | 2010 | 148 | 0.090 |
Why?
|
| Intelligence Tests | 2 | 2021 | 38 | 0.090 |
Why?
|
| Abdominal Pain | 2 | 2004 | 138 | 0.090 |
Why?
|
| Sickness Impact Profile | 1 | 2009 | 26 | 0.090 |
Why?
|
| Cost of Illness | 2 | 2012 | 147 | 0.090 |
Why?
|
| Radiography | 2 | 2005 | 809 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2012 | 727 | 0.090 |
Why?
|
| Muscle, Smooth | 2 | 2002 | 354 | 0.080 |
Why?
|
| Biomarkers | 2 | 2014 | 1755 | 0.080 |
Why?
|
| Device Removal | 1 | 2011 | 167 | 0.080 |
Why?
|
| Methotrexate | 2 | 1986 | 250 | 0.080 |
Why?
|
| Equipment Failure | 2 | 2006 | 121 | 0.080 |
Why?
|
| Tensile Strength | 2 | 2006 | 80 | 0.080 |
Why?
|
| Hydroxyzine | 1 | 2008 | 7 | 0.080 |
Why?
|
| Amitriptyline | 1 | 2008 | 11 | 0.080 |
Why?
|
| Child, Preschool | 2 | 2014 | 3717 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 155 | 0.080 |
Why?
|
| Therapeutic Irrigation | 1 | 2008 | 61 | 0.080 |
Why?
|
| Histamine H1 Antagonists | 1 | 2008 | 40 | 0.080 |
Why?
|
| Medical Audit | 1 | 2008 | 39 | 0.080 |
Why?
|
| Diseases in Twins | 1 | 2008 | 65 | 0.080 |
Why?
|
| Muscle Hypotonia | 1 | 1988 | 48 | 0.080 |
Why?
|
| Office Visits | 1 | 2008 | 50 | 0.080 |
Why?
|
| Health Surveys | 4 | 2012 | 240 | 0.080 |
Why?
|
| Child Behavior | 2 | 2021 | 47 | 0.070 |
Why?
|
| Periodicals as Topic | 1 | 2009 | 168 | 0.070 |
Why?
|
| Analgesics | 1 | 2008 | 119 | 0.070 |
Why?
|
| Urethral Neoplasms | 1 | 1987 | 10 | 0.070 |
Why?
|
| Libido | 1 | 2006 | 8 | 0.070 |
Why?
|
| Preoperative Care | 2 | 2005 | 396 | 0.070 |
Why?
|
| Marriage | 1 | 2006 | 25 | 0.070 |
Why?
|
| Length of Stay | 2 | 2000 | 732 | 0.070 |
Why?
|
| Trophoblasts | 1 | 1986 | 33 | 0.070 |
Why?
|
| Elasticity | 1 | 2006 | 96 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2012 | 2011 | 0.070 |
Why?
|
| Equipment Safety | 1 | 2005 | 33 | 0.070 |
Why?
|
| Muscle Strength | 1 | 2005 | 30 | 0.070 |
Why?
|
| Organizations | 3 | 2010 | 17 | 0.070 |
Why?
|
| Forecasting | 1 | 2007 | 305 | 0.070 |
Why?
|
| Uterine Neoplasms | 3 | 1986 | 245 | 0.060 |
Why?
|
| Family Practice | 1 | 2006 | 82 | 0.060 |
Why?
|
| Cyanates | 1 | 2005 | 1 | 0.060 |
Why?
|
| Vulvitis | 1 | 2005 | 2 | 0.060 |
Why?
|
| Clobetasol | 1 | 2005 | 3 | 0.060 |
Why?
|
| Foreign-Body Reaction | 1 | 2005 | 11 | 0.060 |
Why?
|
| Nerve Block | 1 | 2005 | 50 | 0.060 |
Why?
|
| Demography | 1 | 2005 | 181 | 0.060 |
Why?
|
| Cross-Linking Reagents | 1 | 2005 | 87 | 0.060 |
Why?
|
| Benzofurans | 1 | 2004 | 9 | 0.060 |
Why?
|
| Valsalva Maneuver | 1 | 2004 | 6 | 0.060 |
Why?
|
| Life Tables | 1 | 2004 | 48 | 0.060 |
Why?
|
| Cadaver | 2 | 2004 | 185 | 0.060 |
Why?
|
| Actinomycosis | 1 | 2004 | 12 | 0.060 |
Why?
|
| Central Nervous System | 1 | 2005 | 153 | 0.060 |
Why?
|
| Trophoblastic Neoplasms | 1 | 1984 | 5 | 0.060 |
Why?
|
| Receptor, Cholecystokinin B | 1 | 2004 | 3 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 2004 | 59 | 0.060 |
Why?
|
| Cholecystokinin | 1 | 2004 | 15 | 0.060 |
Why?
|
| Vision Disorders | 1 | 2004 | 75 | 0.060 |
Why?
|
| Genital Diseases, Female | 1 | 2004 | 24 | 0.060 |
Why?
|
| Triplets | 1 | 2003 | 8 | 0.060 |
Why?
|
| Panic Disorder | 1 | 2004 | 21 | 0.060 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 1984 | 27 | 0.060 |
Why?
|
| Electromyography | 1 | 2004 | 193 | 0.060 |
Why?
|
| Twins | 1 | 2003 | 65 | 0.060 |
Why?
|
| Salivation | 1 | 2003 | 3 | 0.060 |
Why?
|
| Northwestern United States | 1 | 2003 | 7 | 0.060 |
Why?
|
| Swine | 1 | 2005 | 581 | 0.060 |
Why?
|
| Obesity | 1 | 2010 | 966 | 0.060 |
Why?
|
| Sexual Behavior | 1 | 2006 | 309 | 0.050 |
Why?
|
| Indigo Carmine | 1 | 2002 | 3 | 0.050 |
Why?
|
| Self Care | 1 | 2004 | 164 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2002 | 65 | 0.050 |
Why?
|
| Congresses as Topic | 1 | 2003 | 112 | 0.050 |
Why?
|
| Transducers, Pressure | 1 | 2001 | 6 | 0.050 |
Why?
|
| Bioprosthesis | 1 | 2002 | 39 | 0.050 |
Why?
|
| Methods | 4 | 1989 | 151 | 0.050 |
Why?
|
| Hippurates | 1 | 2021 | 3 | 0.050 |
Why?
|
| Methenamine | 1 | 2021 | 3 | 0.050 |
Why?
|
| Fiber Optic Technology | 1 | 2001 | 35 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 1043 | 0.050 |
Why?
|
| Intraoperative Complications | 1 | 2002 | 188 | 0.050 |
Why?
|
| Adolescent Development | 1 | 2021 | 21 | 0.050 |
Why?
|
| Fasciitis, Necrotizing | 1 | 2000 | 12 | 0.050 |
Why?
|
| Fasciotomy | 1 | 2000 | 17 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 1996 | 2014 | 0.050 |
Why?
|
| Substance-Related Disorders | 2 | 1996 | 414 | 0.040 |
Why?
|
| Parkinson Disease | 1 | 2002 | 146 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 824 | 0.040 |
Why?
|
| Adolescent Behavior | 1 | 2021 | 109 | 0.040 |
Why?
|
| Bone Screws | 1 | 1999 | 45 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 2 | 2012 | 272 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 2362 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 112 | 0.040 |
Why?
|
| Nickel | 1 | 2019 | 13 | 0.040 |
Why?
|
| Incontinence Pads | 1 | 1999 | 4 | 0.040 |
Why?
|
| Posture | 2 | 1991 | 124 | 0.040 |
Why?
|
| Child Development | 1 | 2021 | 167 | 0.040 |
Why?
|
| Bisacodyl | 1 | 1978 | 1 | 0.040 |
Why?
|
| Patient Selection | 1 | 2002 | 682 | 0.040 |
Why?
|
| Proctitis | 1 | 1978 | 12 | 0.040 |
Why?
|
| Enema | 1 | 1978 | 39 | 0.040 |
Why?
|
| Sacrum | 1 | 2018 | 43 | 0.040 |
Why?
|
| Suppositories | 1 | 1998 | 3 | 0.040 |
Why?
|
| Administration, Rectal | 1 | 1998 | 12 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 1999 | 184 | 0.040 |
Why?
|
| Behavior Therapy | 2 | 1990 | 84 | 0.040 |
Why?
|
| Phosphates | 1 | 1978 | 160 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1984 | 1363 | 0.040 |
Why?
|
| Choriocarcinoma | 3 | 1986 | 7 | 0.040 |
Why?
|
| Urinalysis | 1 | 1997 | 31 | 0.040 |
Why?
|
| General Practice | 1 | 2016 | 9 | 0.030 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 192 | 0.030 |
Why?
|
| Supine Position | 1 | 1996 | 30 | 0.030 |
Why?
|
| Fluocortolone | 1 | 1996 | 1 | 0.030 |
Why?
|
| Retinitis | 1 | 1996 | 3 | 0.030 |
Why?
|
| Curriculum | 1 | 2001 | 567 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 1996 | 64 | 0.030 |
Why?
|
| Urologic Neoplasms | 1 | 1997 | 82 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1978 | 237 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2018 | 341 | 0.030 |
Why?
|
| Uveitis | 1 | 1996 | 31 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 1996 | 229 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2007 | 306 | 0.030 |
Why?
|
| Ovarian Neoplasms | 1 | 2001 | 763 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 859 | 0.030 |
Why?
|
| Schizophrenia, Paranoid | 1 | 1993 | 4 | 0.030 |
Why?
|
| Neuropsychological Tests | 1 | 1996 | 505 | 0.030 |
Why?
|
| Glucocorticoids | 1 | 1996 | 357 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2001 | 1194 | 0.030 |
Why?
|
| Intestinal Mucosa | 1 | 1978 | 805 | 0.030 |
Why?
|
| Crime | 1 | 1993 | 37 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2008 | 771 | 0.030 |
Why?
|
| Schizophrenic Psychology | 1 | 1993 | 133 | 0.030 |
Why?
|
| Infant | 1 | 2019 | 3147 | 0.030 |
Why?
|
| Caregivers | 1 | 2014 | 159 | 0.030 |
Why?
|
| Canada | 1 | 2012 | 208 | 0.030 |
Why?
|
| ROC Curve | 1 | 1995 | 781 | 0.030 |
Why?
|
| Health Status | 1 | 2014 | 370 | 0.030 |
Why?
|
| Alcoholism | 1 | 1993 | 178 | 0.020 |
Why?
|
| Labor Stage, Second | 1 | 2011 | 6 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 3 | 1986 | 72 | 0.020 |
Why?
|
| Electrosurgery | 1 | 2011 | 9 | 0.020 |
Why?
|
| Cephalometry | 1 | 2011 | 50 | 0.020 |
Why?
|
| Prognosis | 2 | 1990 | 3773 | 0.020 |
Why?
|
| Violence | 1 | 1993 | 153 | 0.020 |
Why?
|
| Kidney | 1 | 1997 | 1145 | 0.020 |
Why?
|
| Baths | 1 | 2011 | 8 | 0.020 |
Why?
|
| Therapeutic Equivalency | 1 | 2011 | 13 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2011 | 133 | 0.020 |
Why?
|
| Sunscreening Agents | 1 | 2011 | 8 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2012 | 207 | 0.020 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1990 | 33 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1999 | 2657 | 0.020 |
Why?
|
| Videotape Recording | 1 | 1990 | 48 | 0.020 |
Why?
|
| Fetus | 1 | 2011 | 232 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 337 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 1990 | 157 | 0.020 |
Why?
|
| Physical Therapy Modalities | 1 | 1990 | 83 | 0.020 |
Why?
|
| Massage | 1 | 1989 | 3 | 0.020 |
Why?
|
| Mass Screening | 1 | 2014 | 636 | 0.020 |
Why?
|
| Dilatation | 1 | 1989 | 48 | 0.020 |
Why?
|
| Frail Elderly | 1 | 2010 | 82 | 0.020 |
Why?
|
| Polyuria | 1 | 2009 | 7 | 0.020 |
Why?
|
| Water | 1 | 2011 | 283 | 0.020 |
Why?
|
| Administration, Topical | 1 | 2009 | 96 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 590 | 0.020 |
Why?
|
| Algorithms | 1 | 1997 | 1875 | 0.020 |
Why?
|
| Consensus | 1 | 2010 | 356 | 0.020 |
Why?
|
| Manometry | 1 | 1987 | 44 | 0.020 |
Why?
|
| Hydatidiform Mole, Invasive | 2 | 1984 | 2 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 1990 | 359 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2007 | 150 | 0.020 |
Why?
|
| Pregnancy, Tubal | 1 | 1986 | 4 | 0.020 |
Why?
|
| Cattle | 1 | 2007 | 375 | 0.020 |
Why?
|
| Enuresis | 1 | 1986 | 4 | 0.020 |
Why?
|
| Twin Studies as Topic | 1 | 2006 | 19 | 0.020 |
Why?
|
| Skin Physiological Phenomena | 1 | 2006 | 27 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2007 | 389 | 0.020 |
Why?
|
| Premenopause | 1 | 2006 | 57 | 0.020 |
Why?
|
| Pregnancy, Ectopic | 1 | 1986 | 36 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 1986 | 510 | 0.020 |
Why?
|
| Lasers | 1 | 1986 | 107 | 0.020 |
Why?
|
| Postmenopause | 1 | 2006 | 102 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 479 | 0.020 |
Why?
|
| Focus Groups | 1 | 2006 | 170 | 0.020 |
Why?
|
| Vulva | 1 | 2005 | 23 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2010 | 398 | 0.020 |
Why?
|
| Anesthetics, Local | 1 | 2005 | 76 | 0.020 |
Why?
|
| Cell Division | 1 | 1986 | 696 | 0.020 |
Why?
|
| Linear Models | 1 | 2006 | 421 | 0.020 |
Why?
|
| Shock, Septic | 1 | 1986 | 104 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1986 | 996 | 0.020 |
Why?
|
| Drug Delivery Systems | 1 | 2006 | 179 | 0.020 |
Why?
|
| Genital Neoplasms, Female | 1 | 1986 | 108 | 0.010 |
Why?
|
| Rectus Abdominis | 1 | 2004 | 40 | 0.010 |
Why?
|
| Surgical Instruments | 1 | 2004 | 57 | 0.010 |
Why?
|
| Dermatitis, Contact | 1 | 2003 | 6 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 1986 | 269 | 0.010 |
Why?
|
| Headache | 1 | 2003 | 72 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2004 | 334 | 0.010 |
Why?
|
| Biopsy | 1 | 1986 | 1182 | 0.010 |
Why?
|
| Hydatidiform Mole | 1 | 1982 | 6 | 0.010 |
Why?
|
| Diarrhea | 1 | 2003 | 182 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2004 | 685 | 0.010 |
Why?
|
| Electromagnetic Fields | 1 | 2000 | 26 | 0.010 |
Why?
|
| Analgesics, Opioid | 1 | 2005 | 442 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 2002 | 200 | 0.010 |
Why?
|
| Suction | 1 | 1999 | 35 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 2001 | 162 | 0.010 |
Why?
|
| Debridement | 1 | 1999 | 57 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 1848 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2004 | 1371 | 0.010 |
Why?
|
| Treatment Refusal | 1 | 1996 | 62 | 0.010 |
Why?
|
| Bacteria | 1 | 1999 | 472 | 0.010 |
Why?
|
| Depressive Disorder | 1 | 1996 | 221 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1999 | 786 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1996 | 491 | 0.010 |
Why?
|
| Bipolar Disorder | 1 | 1996 | 386 | 0.010 |
Why?
|
| Pregnancy Tests | 1 | 1986 | 2 | 0.000 |
Why?
|
| Hysterosalpingography | 1 | 1986 | 7 | 0.000 |
Why?
|
| Amenorrhea | 1 | 1986 | 28 | 0.000 |
Why?
|
| Hemoperitoneum | 1 | 1986 | 4 | 0.000 |
Why?
|
| Uterine Hemorrhage | 1 | 1986 | 21 | 0.000 |
Why?
|
| Drug Evaluation | 1 | 1986 | 138 | 0.000 |
Why?
|
| Laparoscopy | 1 | 1986 | 771 | 0.000 |
Why?
|
| Infant, Newborn | 1 | 1982 | 2476 | 0.000 |
Why?
|